Phase II study of 131-iodine-labeled anti-tenascin murine monoclonal antibody 81C6 (M81C6) administered to deliver a targeted radiation boost dose of 44 Gy to the surgically created cystic resection cavity perimeter in the treatment of patients with newly diagnosed primary and metastatic brain tumors
Published
Conference Paper
Full Text
Duke Authors
Cited Authors
- Reardon, D; Akabani, G; Friedman, A; Friedman, H; Herndon, J; McLendon, R; Quinn, J; Rich, J; Vredenburgh, J; Penne, K; Sampson, J; Gururangan, S; Shafman, T; Wong, T; Dowell, J; Dunn, R; Badruddoja, M; Desjardins, A; Affronti, M; Allen, D; Jackson, S; Zeigler, K; Silverman, S; Tourt-Uhlig, S; Coleman, R; Zalutsky, N; Bigner, D
Published Date
- October 1, 2004
Published In
Volume / Issue
- 6 / 4
Start / End Page
- 381 - 381
Published By
Pages
- 1
International Standard Serial Number (ISSN)
- 1522-8517
Conference Name
- 9th Annual Meeting of the Society-for-Neuro-Oncology
Conference Location
- Toronto, CANADA
Conference Start Date
- November 18, 2004
Conference End Date
- November 21, 2004